GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company is headquartered in La Jolla, California and currently employs 3 full-time employees. The company went IPO on 2021-02-10. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Follow-Up Questions
Qui est le CEO de GRI Bio Inc ?
Dr. W. Marc Hertz est le President de GRI Bio Inc, il a rejoint l'entreprise depuis 2023.
Quelle est la performance du prix de l'action GRI ?
Le prix actuel de GRI est de $1.66, il a decreased de 0.41% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de GRI Bio Inc ?
GRI Bio Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de GRI Bio Inc ?
La capitalisation boursière actuelle de GRI Bio Inc est de $4.1M
Est-ce que GRI Bio Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour GRI Bio Inc, y compris 1 achat fort, 4 achat, 1 maintien, 0 vente et 1 vente forte
